menu
    • menu
    [{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CypCaps","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Not Applicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CypCaps","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Not Applicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"CypCaps","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ H.C. Wainwright"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cells","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ H.C. Wainwright"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cells","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"CypCaps","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Not Applicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CypCaps","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaCyte Biotech \/ Heidelberg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Heidelberg Pharma"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"CBSET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CypCaps","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaCyte Biotech \/ CBSET","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ CBSET"}]

    Find Clinical Drug Pipeline Developments & Deals for Ifosfamide

    Menu

    Ifosfamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CBSET

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

                            Details : The objective of this pilot study is to assess microcatheter-based delivery of CypCaps in the pancreatic arterial system. volume of dose, number of CypCaps, and treatment location will be evaluated using imaging and histology.

                            Brand Name : CypCaps

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 21, 2022

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CBSET

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Heidelberg Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

                            Details : The study has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypCaps plus ifosfamide pancreatic cancer therapy for the treatment of mal...

                            Brand Name : CypCaps

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 19, 2022

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Heidelberg Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

                            Details : Analysis after 18 months in storage at -80oC, the unfrozen CypCaps product passed all the specified tests, including cell viability, enzyme activity, cell potency, pH, label check, capsule appearance and integrity.

                            Brand Name : CypCaps

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encapsulated Live Cells,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $90.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Ca...

                            Details : PharmaCyte is positioned to immediately move into a fully funded clinical trial in LAPC should the FDA lift the clinical hold.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 25, 2021

                            Lead Product(s) : Encapsulated Live Cells,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $90.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encapsulated Live Cells,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : H.C. Wainwright

                            Deal Size : $70.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasd...

                            Details : The Company intends to use the net proceeds of this offering to complete activities requested by the U.S. Food and Drug Administration (FDA) to address the FDA’s clinical hold on its Investigational New Drug application (IND).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 23, 2021

                            Lead Product(s) : Encapsulated Live Cells,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : H.C. Wainwright

                            Deal Size : $70.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : H.C. Wainwright

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

                            Details : PharmaCyte's CypCapsTM, is a genetically engineered human cells encapsulated using the Cell-in-a-Box® technology. PharmaCyte is conducting a Phase 2b study to evaluate the efficacy and safety of CypCaps in combination with low-dose ifosfamide vs chemora...

                            Brand Name : CypCaps

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 09, 2021

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : H.C. Wainwright

                            Deal Size : $15.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy

                            Details : The DMF provides all confidential and detailed information covering the production of the CypCaps™ final product, which was produced by Austrianova and will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic can...

                            Brand Name : CypCaps

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 27, 2020

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            PharmaCyte Biotech

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PharmaCyte Biotech Successfully Develops “Change History” for its Clinical Trial Product for Pancreatic Ca...

                            Details : PharmaCyte has successfully completed development of the “change history” information and data for CypCaps™ (2nd generation product) compared to CapCell™ (1st generation product).

                            Brand Name : CypCaps

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 10, 2020

                            Lead Product(s) : CypCaps,Ifosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth